Quality of Life and Cost Considerations: Y-90 Radioembolization. Semin Intervent Radiol 2021 Oct;38(4):482-487
Date
10/12/2021Pubmed ID
34629718Pubmed Central ID
PMC8497083DOI
10.1055/s-0041-1735570Scopus ID
2-s2.0-85116894058 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Objective Transarterial radioembolization (TARE) offers a minimally invasive and safe treatment option for primary and metastatic hepatic malignancies. The benefits of TARE are manifold including prolonged overall survival, low associated morbidities, and improved time to progression allowing prolonged treatment-free intervals. The rapid development of new systemic therapies including immunotherapy has radically changed the treatment landscape for primary and metastatic liver cancer. Given the current climate, it is critical for interventional oncologists to understand the benefits of TARE relative to these other therapies. Therefore, this report aims to review quality-of-life outcomes and the cost comparisons of TARE as compared with systemic therapies.
Author List
Williams SJ, Rilling WS, White SBAuthors
William S. Rilling MD, FSIR Vice Chair, Professor in the Radiology department at Medical College of WisconsinSarah B. White MD, MS, FSIR, FCIRSE Associate Dean, Assistant Provost, Professor in the Radiology department at Medical College of Wisconsin
